Renovis, Pfizer to collaborate on pain research

South San Francisco-based Renovis has inked a deal to collaborate with Pfizer on research into the VR1 receptor that could be worth up to $170 million. Renovis will gain a $10 million licensing fee and $7 million in research money for the next two years. The two companies will focus on developing an inhibitor on VR1, a protein that plays a role in inflicting pain.

- read this article from MSN for more on the deal

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.